Magnesium sulphate attenuates arterial blood pressure increase during laparoscopic cholecystectomy under pneumoperitoneum

Magnesium sulphate attenuates arterial blood pressure increase during laparoscopic cholecystectomy under pneumoperitoneum - Magnesium sulphate during laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001929

Enrollment

Registered

2009-05-01

Start date

2005-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for elective laparoscopic cholecystectomy under CO2 pneumoperitoneum

Interventions

0.5 ml/kg of 10% magnesium sulphate (50 mg/kg) intravenously injection before pneumoperitoneum 0.5 ml/kg saline intravenously injection before pneumoperitoneum

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA physical status 1 patients scheduled for elective laparoscopic cholecystectomy under CO2 pneumoperitoneum

Exclusion criteria

Exclusion criteria: Patients with following criteria 1. hypermagnesaemia 2. a known allergy to magnesium sulphate 3. any degree of heart block hypertension, diabetes mellitus, cardiovascular diseases or kidney dysfunction 4. acute cholecystitis 5. an endocrine or metabolic disease

Design outcomes

Primary

Measure	Time frame
Hemodynamic stability during intraoperative period	—

Secondary

Measure	Time frame
neurohumoral responses in patients undergoing laparoscopic cholecystectomy	—

Countries

Asia(except Japan)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026